Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer.

Honma Y, Shimada Y, Takashima A, Iwasa S, Kato K, Hamaguchi T, Yamada Y, Taniguchi H, Sekine S, Kushima R.

Int J Clin Oncol. 2014 Oct;19(5):863-70. doi: 10.1007/s10147-013-0629-3. Epub 2013 Nov 12.

PMID:
24218279
2.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators.

Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Erratum in: Lancet. 2010 Oct 16;376(9749):1302.

PMID:
20728210
3.

Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).

Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, Komatsu Y, Doki Y, Tsujinaka T, Furukawa H.

Br J Cancer. 2014 Mar 4;110(5):1163-8. doi: 10.1038/bjc.2014.18. Epub 2014 Jan 28.

4.

A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).

Kataoka K, Tokunaga M, Mizusawa J, Machida N, Katayama H, Shitara K, Tomita T, Nakamura K, Boku N, Sano T, Terashima M, Sasako M; Stomach Cancer Study Group/Japan Clinical Oncology Group.

Jpn J Clin Oncol. 2015 Nov;45(11):1082-6. doi: 10.1093/jjco/hyv134. Epub 2015 Sep 9.

PMID:
26355164
5.

Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.

Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, Tham CK, Ng M, Tai DW, Iwasa S, Lim HY, Choo SP.

Cancer Chemother Pharmacol. 2015 Aug;76(2):397-408. doi: 10.1007/s00280-015-2811-y. Epub 2015 Jun 24.

PMID:
26099969
6.

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.

Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, Kimura T, Yamanaka T, Shitara K, Nagatsuma AK, Yoshino T, Ochiai A, Ohtsu A.

Gastric Cancer. 2016 Jan;19(1):183-91. doi: 10.1007/s10120-015-0471-6. Epub 2015 Feb 15.

PMID:
25682441
7.

A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.

Shitara K, Sawaki A, Matsuo K, Kondo C, Takahari D, Ura T, Tajika M, Niwa Y, Muro K.

Int J Clin Oncol. 2013 Jun;18(3):539-46. doi: 10.1007/s10147-012-0416-6. Epub 2012 May 3.

PMID:
22552360
8.

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.

Sawaki A, Ohashi Y, Omuro Y, Satoh T, Hamamoto Y, Boku N, Miyata Y, Takiuchi H, Yamaguchi K, Sasaki Y, Nishina T, Satoh A, Baba E, Tamura T, Abe T, Hatake K, Ohtsu A.

Gastric Cancer. 2012 Jul;15(3):313-22. doi: 10.1007/s10120-011-0118-1. Epub 2011 Dec 17.

9.

A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II).

Tsuburaya A, Morita S, Kodera Y, Kobayashi M, Shitara K, Yamaguchi K, Yoshikawa T, Yoshida K, Yoshino S, Sakamoto J.

BMC Cancer. 2012 Jul 23;12:307. doi: 10.1186/1471-2407-12-307.

10.

[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].

Shen L, Xu JM, Feng FY, Jiao SC, Wang LW, Li J, Guan ZZ, Qin SK, Wang JJ, Yu SY, Wang YJ, Jin YN, Tao M, Zheng LZ, Pan LX.

Zhonghua Zhong Liu Za Zhi. 2013 Apr;35(4):295-300. doi: 10.3760/cma.j.issn.0253-3766.2013.04.012. Chinese.

PMID:
23985260
11.

[Two cases of unresectable advanced gastric cancer treated with S-1, CDDP and trastuzumab].

Ogino T, Kawamura M, Tsutsumi K, Sakamoto N, Kodama H, Machida T, Takahashi T, Takanashi S, Nakamura Y, Ishii R.

Gan To Kagaku Ryoho. 2013 Feb;40(2):237-40. Japanese.

PMID:
23411963
12.

A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.

Kataoka H, Mori Y, Shimura T, Nishie H, Natsume M, Mochizuki H, Hirata Y, Sobue S, Mizushima T, Sano H, Mizuno Y, Nakamura M, Hirano A, Tsuchida K, Adachi K, Seno K, Kitagawa M, Kawai T, Joh T.

Cancer Chemother Pharmacol. 2016 May;77(5):957-62. doi: 10.1007/s00280-016-3013-y. Epub 2016 Mar 22.

PMID:
27002325
13.

[HER2 and gastric cancer: a novel therapeutic target for trastuzumab].

Bouché O, Penault-Llorca F.

Bull Cancer. 2010 Dec;97(12):1429-40. doi: 10.1684/bdc.2010.1224. Review. French.

14.

Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

Norman G, Rice S, Spackman E, Stirk L, Danso-Appiah A, Suh D, Palmer S, Eastwood A.

Health Technol Assess. 2011 May;15 Suppl 1:33-42. doi: 10.3310/hta15suppl1/04. Review.

15.

Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer.

Tsushima T, Hironaka S, Boku N, Machida N, Yamazaki K, Yasui H, Fukutomi A, Todaka A, Taniguchi H, Onozawa Y, Taku K.

Int J Clin Oncol. 2013 Feb;18(1):10-6. doi: 10.1007/s10147-011-0335-y. Epub 2011 Oct 22.

PMID:
22020563
16.

Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.

Palacio S, Loaiza-Bonilla A, Kittaneh M, Kyriakopoulos C, Ochoa RE, Escobar M, Arango B, Restrepo MH, Merchan JR, Rocha Lima CM, Hosein PJ.

Anticancer Res. 2014 Jan;34(1):301-6.

PMID:
24403478
17.

[A case of SPT therapy( S-1+CDDP+trastuzumab) was successful for HER2-positive gastric cancer accompanied by distant lymph node metastasis].

Hyuga N, Kobayashi K, Watanabe R, Chono A, Matsumoto T, Takemoto H, Takachi K, Nishioka K, Aoki T, Uemura Y, Yoshida K.

Gan To Kagaku Ryoho. 2013 Nov;40(12):2256-8. Japanese.

PMID:
24394077
18.

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.

Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, Wang J, Xu N, Cheng Y, Bai Y, Liu W, Wang L, Shen L.

BMC Cancer. 2016 Feb 8;16:68. doi: 10.1186/s12885-016-2092-9.

19.

Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.

Koizumi W, Tanabe S, Azuma M, Ishido K, Nishimura K, Sasaki T, Nakatani K, Higuchi K, Nakayama N, Katada C.

Int J Cancer. 2010 Jan 1;126(1):162-70. doi: 10.1002/ijc.24726.

20.

[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].

Murata Y, Matsuura T, Kanoshima K, Kuwabara H, Fuyuki A, Tomeno W, Taniguchi R, Uchiyama T, Kuriyama H, Hata Y.

Gan To Kagaku Ryoho. 2013 Jul;40(7):933-6. Japanese.

PMID:
23863740

Supplemental Content

Support Center